Despite a critical landmark positive vote in the US House of Representatives, experts say investors will still have to wait longer for significant changes in the cannabis space.

The Secure and Fair Enforcement Banking Act of 2019, designed to protect banking actions for marijuana companies in the US, was approved in the House of Representatives on Wednesday (September 25) by a vote of 321 in favor, compared to 103 against.

The positive vote for the bill represents the first cannabis-related legislation to pass through Congress. If approved, the bill will create protections for banks and other financial institutions willing to offer banking services to cannabis and hemp companies in the US.

The bill, commonly referred to as the SAFE Banking Act, has gained status as a significant catalyst for the state of cannabis stocks.

However, as mentioned, financial experts believe investors will have to wait for fundamental changes to see any kind of run in the market.

After a harsh summer for marijuana stocks, during which a pullback was recognized by the market, optimism about the effect of a positive vote in the House of Representatives has been increasing. But many experts are encouraging caution.

“I’d be careful. They could rally, but I wouldn’t suggest that’s going to be something enormous,” Matthew Pallotta, equity research analyst at Echelon Wealth Partners, told the Investing News Network (INN) on the eve of the vote. Pallotta covers the US market and multi-state operators (MSOs) for Echelon Wealth.

Prior to the vote, the analyst said a positive outcome would represent a solid development for the sentiment in the market, but, fundamentally, the changes will not come immediately.

“I think the market realizes that one of the biggest hurdles remains — the Senate — and there’s nothing really concrete there yet,” he said.

The bill, which will now move onto its path in the Senate, would prohibit federal authorities from punitive action against banks for working and offering services to marijuana and hemp businesses.

This would offer banking relief to US-based companies, including MSOs, operating in the space.

Marc Adesso, veteran cannabis attorney with law firm Waller Lansden Dortch and Davis, told INN that presently it’s unclear how the bill will fare in the Senate.

The lawyer said it will be difficult to predict the fate of the bill in the Republican-controlled Senate.

In order to pass through the House, the act needed to get 290 votes, or a two-thirds majority. According to the National Cannabis Industry Association (NCIA), the bill had 206 co-sponsors in the House.

In a series of tweets, Todd Harrison, chief investment officer with investment firm CB1 Capital, said he expects the bill to pass the Senate at a later date this year.

Looking ahead, Harrison said the potential events that could shake the industry are the closing of merger and acquisition transactions in the US following requests from the Department of Justice and a ramp up in the election talk surrounding the legalization of the drug.

Nawan Butt, associate portfolio manager Purpose Investments, told INN there’s a lot of optimism in the industry as a whole for the potential for this bill to pass in 2019.

“The industry is hanging onto the hope that this would make it a lot easier for a lot of these bigger plays to grow a lot quicker, capture market share and bring over the black market to legal channels,” he said.

Aaron Smith, executive director of the NCIA, said the SAFE Banking Act would offer a chance to small businesses, including those owned and operated by people in marginalized communities, to participate in the industry by way of gaining access to traditional lending.

“Current banking regulations disproportionately hurt small businesses, women, and people of color,” he explained. “We cannot afford to wait any longer while they are being excluded from the opportunities created by legal cannabis markets.”

Editor’s note: This story and headline were updated to reflect the vote in the House of Representatives.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less